A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency
- PMID: 39756409
- PMCID: PMC12448196
- DOI: 10.1093/cei/uxae121
A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency
Abstract
Background: Acquired angioedema due to C1-inhibitor deficiency (AAE-C1-INH) is very rare compared to its prototype, hereditary angioedema. An updated characterization of the AAE-C1-INH cohort in the UK is required to inform management.
Objectives: To describe the disease burden of AAE-C1-INH, long-term prophylaxis (LTP) and the clinical, immunochemical, and treatment profiles of AAE-associated diseases in the UK.
Method: Retrospective data on 117 AAE-C1-INH patients were collected using a national survey proforma across 25/34 Adult Clinical Immunology and Allergy centres in the UK. Other European cohorts were compared.
Results: The median age at AAE-C1-INH diagnosis was 65 years with 3.4% of patients diagnosed below 40 years. The median delay in diagnosis was 1 year. Antifibrinolytics and attenuated androgens showed comparable efficacy to LTP, at 88.9% and 89.5%, respectively. A haematological disorder was identified in 83.8% of AAE-C1-INH patients compared to 3.4% of autoimmune diseases. The predominant haematological disorders were splenic marginal zone lymphoma 34% followed by MGUS 16%. The severity of angioedema did not depend on the associated disease. Anti-C1INH-autoantibodies testing was limited to 23.1%. Rituximab monotherapy was effective in treating 9/9 splenic marginal zone lymphoma and 1/2 MGUS-associated AAE-C1-INH. Rituximab efficacy was independent of anti-C1INH-autoantibodies detection with response in 3/3 seronegative and 4/4 seropositive patients.
Conclusion: The diagnosis of AAE-C1-INH should not be overlooked below the age of 40 years. The choice of oral LTP should be informed by the propensity to side effects. B cell depletion could be considered in treating monoclonal B cell disorder-associated-AAE-C1-INH in the absence of haematological indications. Further studies are required to address the clinical utility of anti-C1INH-autoantibodies.
Keywords: MGUS; angioedema due to acquired C1 inhibitor deficiency; anti-C1 inhibitor autoantibodies; long-term prophylaxis; rituximab; splenic marginal zone lymphoma.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
A Manson received honoraria from CSL Behring, BioCryst, and Takeda for educational events and advisory boards. A Herwadkar received support for attending meetings from BioCryst, Pharming, and Takeda. E Cleave attended Takeda-sponsored management course (Amplify Rare) 2022. C Steele received advisory work and educational support from BioCryst, CSL Behring, Pharming, and Takeda. L Lorenzo received consulting, advisory work, and educational support from BioCryst, Pharming, and Takeda. M Dziadzio received support to attend educational meetings from CSL and Takeda. M Ahuja Received honoraria from BioCryst and Takeda for educational events and advisory boards. M Frleta-Gilchrist received support for attending a meeting from BioCryst. P Yong received consulting fees, honoraria, and/or support for attending meetings from Astria Therapeutics, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, and Takeda. S Elkhalifa received funds as part of an Advisory Board or expert consultation from BioCryst, CSL, and Takeda Pharmaceutical Companies, none of these funds related to this article. T El-Shanawany received educational support, research support, speaker fees, and/or consultant fees from ALK-Abello, Allergy Therapeutics, CSL, KalVista, Octapharma, Novartis, Takeda, and Viatris. T Garcez received consulting, advisory work, and educational support from BioCryst, CSL Behring, Novartis, Octapharma, Pharming, and Takeda. R Jain received educational support and advisory support from Takeda, Pharming, CSL Behring, and BioCryst. The rest of the authors do not have a conflict of interest to declare.
References
-
- Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol 2017, 5, 1307–13. doi: https://doi.org/ 10.1016/j.jaip.2016.12.032 - DOI - PubMed
-
- Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy 2022, 77, 1961–90. doi: https://doi.org/ 10.1111/all.15214 - DOI - PubMed
-
- Gobert D, Paule R, Ponard D, Levy P, Frémeaux-Bacchi V, Bouillet L, et al. A nationwide study of acquired C1-inhibitor deficiency in France. Medicine (Baltimore) 2016, 95, e4363. doi: https://doi.org/ 10.1097/MD.0000000000004363 - DOI - PMC - PubMed
-
- Bork K, Staubach-Renz P, Hardt J.. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis 2019, 14, 65. doi: https://doi.org/ 10.1186/s13023-019-1043-3 - DOI - PMC - PubMed
-
- Polai Z, Balla Z, Varga L, Benedek S, Farkas H.. Long term follow-up of complement parameters to improve the management of acquired angioedema due to C1-inhibitor deficiency. Heliyon 2022, 8, e11292. doi: https://doi.org/ 10.1016/j.heliyon.2022.e11292 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources